Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,150.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High
February 02, 2024
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Earnings Scheduled For February 2, 2024
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
Earnings Outlook For Regeneron Pharmaceuticals
February 01, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views
January 29, 2024
Via
Benzinga
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
Via
InvestorPlace
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
February 01, 2024
The company missed total sales and earnings expectations.
Via
Investor's Business Daily
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
January 29, 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
Via
Benzinga
Exposures
Product Safety
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) qualifies as a quality stock.
January 12, 2024
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Could Regeneron Stock Help You Retire a Millionaire?
January 10, 2024
The blossoming biotech might give more than a nudge to investors in this project.
Via
The Motley Fool
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock
January 09, 2024
Via
Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
January 23, 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
January 12, 2024
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.